Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isolated Pelvic Perfusion vs Standard Treatment in Recurrent Pelvic Cancer
NCT00949039Phase 3Completed
- Sponsor
- Gustave Roussy
- Start
- Feb 2009
- Primary completion
- Mar 2014
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of tumor necrosis factor-α, melphalan in Pelvic cancer, gynecologic cancer, gastrointestinal cancer, sponsored by Gustave Roussy. Started Feb 2009; status: completed.
02
Drugs
tumor necrosis factor-αmelphalan
03
Conditions
Pelvic cancergynecologic cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT00949039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00949039.